NCT06043232

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

The Role and Mechanism of MMR/MSI Phenotypes in Evaluating Vaccine Benefit in Glioblastoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 360 (estimated)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed. Tumor vaccines has been shown to improve survival of GBM, but not all patients can benefit from vaccine treatment and biomarkers are urgently needed. Deletion of mismatch repair (MMR) protein and microsatellite instability (MSI) state are important features in the biological evolution of GBM, and may be used as markers for tumor vaccine. Therefore, this project will collect samples from GBM patients before and after vaccine treatment respectively, and evaluate the role of MMR/MSI gene phenotype in predicting vaccine efficacy and the potential molecular mechanism. Moreover, MMR/MSI phenotypes will be assessed by deep-learning and radiomics using images to establish noninvasive markers for vaccine.

Conditions

• Glioma

Interventions

Type	Name	Description
BIOLOGICAL	DC vaccine	DC vaccine produced by the Team

Timeline

• Start date: 2023-09-01
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2023-09-21
• Last updated: 2023-09-21

Locations

1 site across 1 country: China